Recent news and publications

News

Researchers make progress understanding a rare pediatric cancer

Publications

Abstracts

Bagatell R, Gore L, Egorin M, Ho R, Heller R, Boucher N, Zuhowski E, Whitlock J, Hunger S, Narendran A, Katzenstein H, Arceci R, Boklan J, Herzog C, Whitesell L Ivy S, and Trippett T. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics consortium study. Clin Cancer Research 2007; 13(6): 1783-1788.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R and Narendran A. Effects of Hsp90 inhibition in neuroblastoma: Analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. J Novel Therap Oncol 2008; 7(3):183-93.

Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, and Strother D. Establishment of atypical-teratoid /rhabdoid tumor (ATRT) cell cultures from disseminated CSF cells: A model to elucidate biology and potential targeted therapeutics. J Neurooncol 2008; 90(2):171-80.

Psaila B and Lyden D. The metastatic niche: adapting the foreign soil. Nature Reviews Cancer 2009; 9(4):285-93.

Jayanthan A, Howard S, Trippett T, Horton T, Daisley L, Lewis V, Whitlock J, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737. Leukemia and Lymphoma 2009; 50(7):1174-82.

Trippett T, Herzog C, Whitlock J, Wolff J, Kuttesch K, Bagatell R, Hunger S, Boklan J, Smith A, Arceci R, Katzenstein H, Harbison C, Zhou X, Lu H, Langer C, Weber M, and Gore L. Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators’ Consortium (POETIC). J Clin Oncol 2009; 27(30):5102-8.

 Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E,  Macy ME, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L.   Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors.  Clinical Cancer Research 2011; 17(3):611-9.

 Hoesksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systemic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for identification of a Candidate Drug Repertoire for MLL-rearranged leukemia. Onco Targets 2011; 4:149-68.

Baderali U, Jayanthan A, Hoeksma K, Narendran A,Giles W. W. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. J Neurooncol. 2012 Mar;107(1):111-9.

Farrar JE, Vlachos A, Atsidaftos E, Carlson-Donohoe H, Markello TC, Arceci RJ, Ellis SR, Lipton JM, Bodine DM. Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood. 2011 Dec 22;118(26):6943-51.

Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011 Feb 10;29(5):551-65.

Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2011 Sep 20. [Epub ahead of print]

Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs. 2011 Oct;20(10):1455-67. Epub 2011 Sep 2.

Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug;104(1):179-89.

Grill J, Puget S, Andreiuolo F, Philippe C, Macconaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2011 Dec 20. doi: 10.1002/pbc.24060. [Epub ahead of print]

Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Paediatr Anaesth. 2011 Mar;21(3):255-65.

Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int. 2011 Dec 29;11(1):44.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011 Feb;56(2):211-6.

Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar R, Handler MH, Foreman NK. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol. 2011 Dec;13(12):1296-307

Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer; 2012. 59(7):1252-1258.

Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A. Occurrence and Modulation of Therapeutic Targets of Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. Leuk Lymphoma 2012. Jul; 54(7):1505-1516.

Mineyko A, Narendran A, Fritzler ML, Wei XC, Schmeling H, Kirton A. Inflammatory biomarkers of pediatric focal cerebral arteriopathy. Neurology 2012;79(13):1406-1408.

Steele M and Narendran A. Mechanisms of Defective Erythropoiesis and Anemia in Pediatric Acute Lymphoblastic Leukemia (ALL). Ann Hematol. 2012; 91(10):1513-1518.

de Oliveira C,  Brassesco MS, Scrideli CA, Tone LG and Narendran A. MicroRNA Expression and Activity in Pediatric Acute Lymphoblastic Leukemia (ALL). Pediatric Blood and Cancer 2012; 59(4):599-604.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE. Polo-Like Kinase 1 (PLK1) Inhibition Kills Glioblastoma Multiforme Brain Tumour Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells 2012; 30(6):1064-75. 2012.

 Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendran A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L. A multi-center phase 1b study of oxaliplatin (NSC# 266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatric Blood Cancer 2013; 60(2): 230-6.

Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors. Clin Cancer Res 2013; 19(13):3649-58.

Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol 2013; 7(3):497-512.

Lun X, Ruan Y, Jayanthan A, Liu DJ, Singh A, Trippett T, Bell J, Forsyth P, Johnston RN, Narendran A. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol 2013; 7(5):944-54.

Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nature Medicine 2013; 19 (9):1104-1109.

August KJ, Narendran A, Neville KA. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs. 2013; 73(5):439-461.

Sooriyaarachchi M, Narendran A, Gailer J. N-Acetyl-l-cysteine modulates the metabolism of cisplatin in human plasma in vitro. Metallomics 2013. 5(3):197-207.

Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013; 7(3):497-512.

Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, Hawkins C, Ramaswamy V, Bouffet E, Taylor MD, Singhal A, Maxwell CA, Rassekh R, Yip S, Northcott P, Singh SK, Dunham C, Dunn SE. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase PLK1 as a molecular target in high-risk children. Cancer Res. 2013;73(22):6734-44.

Thakur B, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, Williams C, Rodriguez-Barrueco R, Silva JM, Zhang W, Hearn S, Elemento O, Paknejad N, Manova-Todorova K, Welte K, Bromberg J, Peinado H, Lyden D.  Cell Research. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Research 2014; 24(6): 766-769.

Aurora kinases as druggable targets in pediatric leukemia: Heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. PloS One 2014; 9(7):e102741.

Kieran M et al. Final results of a prospective multi-institutional phase ii study of everolimus (rad001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A POETIC Consortium trial. Neuro Oncol 2014; 16(Suppl 3): iii27.

Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, Anderson C, Blough MD, Cairncross JG, Lafay-Cousin L, Strother D, Hawkins C, Narendran A, Huang A, Chan JA. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol. 2014;16 (1):62-71.

Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15(2):2494-516.

Singh A, Ruan Y, Trippett T and Narendran A. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. Revised and accepted for publication in Journal of Experimental & Clinical Cancer Research. J Exp Clin Cancer Res.; 34(1):104.

Sooriyaarachchi M, White WM, Narendran A, Gailer J. Chemoprotection by d-methionine against cisplatin-induced side-effects: insight from in vitro studies using human plasma. Metallomics. 2014; 6(3):532-41.

 Jayanthan A, Ruan Y, Truong TH, Narendran A. Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. PLoS One. 2014;9(7):e102741.

Lui J, Narendran A, Cawthorpe D. What can population-based physician billing data tell us about the prevalence, costs and disorders associated with different types of cancers based on the 16 years prevalence of cancer diagnosis? Journal of Hospital Administration. 2014; (4): 9-19.

Morris TT, Ruan Y, Lewis VA, Narendran A, Gailer J. Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro. Metallomics. 2014; 6(11):2034-41.

Lun X, Ruan Y, Jayanthan A, Liu DJ, Singh A, Trippett T, Bell J, Forsyth P, Johnston RN, Narendran A. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. Oct; 7(5):944-54.

Singh A, Ruan Y, Trippett T, Narendran A. Targeted Inhibition of MEK1 by Cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. J Exp & Clinical Cancer Res 2015; 34:104.

Yibing P, Maneka R J, Boklan J, Truong T, Trippett T, Narendran A. Targeting MAPK pathway in refractory pediatric leukemia: In vitro cytotoxicity, target modulation and drug combination studies of the specific MEK-1 inhibitor GDC-0973. Leukemia and Lymphoma (Submitted for publication).

Costa-Silva B, Aiello NM, Ocean AJ et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biol. 2015; 17(6):816-26.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015; 527(7578):329-35.

Ruan Y, Kovalchuk A, Jayanthan A, Lun X, Nagashima Y, Kovalchuk O, Wright Jr. JR, Pinto A, Kirton A,  Anderson R, Narendran A. Druggable Targets in Pediatric Neurocutaneous Melanocytosis (NCM):  Molecular and drug sensitivity studies in xenograft and ex-vivo tumor cell culture to identify agents for therapy. Neuro Oncol. 2015; 17(6):822-31.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol. 2015; 17(8):1086-94.

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer 2017; Epub Apr 14.

Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer 2017; (Epub).

Book chapters

Narendran A, Leung A, Ho J. Influence and Implications of Nutrition and Metabolic Factors on the Growth and Survival of Pediatric Cancer Cells: The IGF Connection. Obesity and Cancer Research, Editors: Pauline R. Ramonde and Eva H. Fochas. Nova Science Publishers, Hauppauge NY. 2009.

Ho, J. Leung, A. Narendran A. Obesity as a Complication of Cancer in Children in Overweightness and Walking. Editors: Caleb I. Black. Nova Scientific Publishers, NY. Sep 2010.

 Lamers, F and Narendran A. Pathways of Intrinsic Apoptosis in Neuroblastoma: Targets for Therapeutics and New Drug Development. In, Neuroblastoma. Editor: Prof. Hiroyuki Shimada. In Tech Scientific Publishers. Apr 2013.

Books

Cancer Metastasis - Biologic Basis and Therapeutics - By David Lyden, Danny R. Welch and Bethan Psaila. Cambridge University Press, April 2011.

Reviews

Gore L and Trippett T. Emerging non-transplant strategies in treating pediatric non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports 2010; 5(4):177-84.

Donate to the POETIC FOUNDATION

 Pediatric Oncology Experimental Therapeutics Investigators' Consortium

© Copyright 2018   |   Website designed by Amanda M. Buckley

Connect

toll-free
(877) 769-4828

email
POETIC@poeticphase1.org